Vanderbilt Clinical Score of Das et al for Predicting Progression-Free Survival for a Patient with a Neuroendocrine Tumor Following Lu-177 Dotatate Therapy

Description

Das et al reported a clinical score for predicting progression-free survival (PFS) for a patient with a neuroendocrine tumor (NET) who is treated with Lu-177-Dotatate. The authors are from Vanderbilt Ingram Cancer Center (VICC).

Patient selection: neuroendocrine tumor (NET)

Parameters:

(1) number of available treatments options (outside of peptide receptor radionucleotide therapy, PRRT) for tumor type (based on location)

(2) prior systemic treatments

(3) disease-related symptoms prior to PRRT

(4) tumor burden in critical organs

(5) peritoneal carcinomatosis

Parameter	Finding	Points
available treatments	pancreatic NET	0
	non-pancreatic, non-thymic NET (GI, lung, unknown)	1
	thymic NET	2
prior systemic treatments	none or only treated with a somatostatin analog	0
	treated with a non-chemotherapy treatment beyond a somatostarin analog	1
	chemotherapy for an appropriate indication	2
disease-related symptoms	asymptomatic	0
	Grade 1	1
	>= Grade 2	2
tumor burden in critical organs	other than those listed below	0
	abuts mesenteric vessel; vena cava; >= 5 asymptomatic bone metastases; any symptomatic bone metastases; 25-49% liver involvement; bulky hilar/mediastinal lymph nodes	1
	cardiac; orbital; brain; spinal cord; ureteral with hydronephrosis; gastric outlet; encased mesenteric vessels; compressed tracheobronchial tree; pathologic bone fracture; >= 50% hepatic involvement	2
peritoneal carcinomatosis	no	0
	yes	1

where:

• The site of tumor origin is associated with the number of available treatment options.

total score =

= SUM(points for all of the parameters)

Interpretation:

• minimum score: 0

• maximum score: 9

• If a patient is treated with Lutetium-177 (177Lu)-Dotatate, then the score correlates with progression-free survival.

To read more or access our algorithms and calculators, please log in or register.